Effect of Grape seed extract in treatment of fatty liver

Investigation the effect of Grapex on serum biochemical factors in Non-alcoholic Fatty Liver Disease

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200921048783N2

Enrollment

Registered

2021-07-22

Start date

2021-08-23

Completion date

Unknown

Last updated

2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fatty liver. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Intervention group: Treatment and receiving Grapex capsule (Grape seed extract) 200 mg daily for 2 mounths. Intervention 2: Control group: Receiving placebo capsule daily for 2 mounts

Eligibility

Sex/Gender

All

Age

20 Years to 50 Years

Inclusion criteria

Inclusion criteria: Patients diagnosed with fatty liver BMI equal to 30-40

Exclusion criteria

Exclusion criteria: Unwilling to enter the study Sensitivity to Grapex capsules

Design outcomes

Primary

Measure	Time frame
Aspart amino transferase. Timepoint: Beginning of the study and 2 months after treatment. Method of measurement: Blood sample.;Alanin amino transferase. Timepoint: Beginning of the study and 2 months after treatment. Method of measurement: Blood sample.;Triglyceride. Timepoint: Beginning of the study and 2 months after treatment. Method of measurement: Blood sample.;Cholesterol. Timepoint: Beginning of the study and 2 months after treatment. Method of measurement: Blood sample.;High density lipoprotein. Timepoint: Beginning of the study and 2 months after treatment. Method of measurement: Blood sample.;Low density lipoprotein. Timepoint: Beginning of the study and 2 months after treatment. Method of measurement: Blood sample.;Antioxidant total capacity. Timepoint: Beginning of the study and 2 months after treatment. Method of measurement: Blood sample.	—

Measure

Time frame

Aspart amino transferase. Timepoint: Beginning of the study and 2 months after treatment. Method of measurement: Blood sample.;Alanin amino transferase. Timepoint: Beginning of the study and 2 months after treatment. Method of measurement: Blood sample.;Triglyceride. Timepoint: Beginning of the study and 2 months after treatment. Method of measurement: Blood sample.;Cholesterol. Timepoint: Beginning of the study and 2 months after treatment. Method of measurement: Blood sample.;High density lipoprotein. Timepoint: Beginning of the study and 2 months after treatment. Method of measurement: Blood sample.;Low density lipoprotein. Timepoint: Beginning of the study and 2 months after treatment. Method of measurement: Blood sample.;Antioxidant total capacity. Timepoint: Beginning of the study and 2 months after treatment. Method of measurement: Blood sample.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHoda Mojiri-Forushani

Abadan University of Medical Sciences

dr.mojiri@yahoo.com+98 61 5338 4004

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026